검색
Ultragenyx Pharmaceutical Inc
RARE관심 목록에 추가
32.814USD
-0.576-1.72%
시장 운영 시간 （ET）시세는 15분 지연됩니다
3.23B시가총액
손실P/E TTM
자세한 내용은 Ultragenyx Pharmaceutical Inc 회사
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ultragenyx Pharmaceutical Inc 정보
종목 코드 RARE
회사 이름Ultragenyx Pharmaceutical Inc
상장일Jan 31, 2014
CEOKakkis (Emil D)
직원 수1294
유형Ordinary Share
회계 연도 종료Jan 31
주소60 Leveroni Ct
도시NOVATO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94949
전화14154838800
웹사이트https://www.ultragenyx.com/
종목 코드 RARE
상장일Jan 31, 2014
CEOKakkis (Emil D)
Ultragenyx Pharmaceutical Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
25.38K
+30.54%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
22.21K
+9.05%
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
자주 묻는 질문
Ultragenyx Pharmaceutical Inc의 상위 5대 주주는 누구인가요?
Ultragenyx Pharmaceutical Inc의 상위 5대 주주는 다음과 같습니다: Dr. Emil D. Kakkis, M.D., Ph.D.
Ultragenyx Pharmaceutical Inc(RARE)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Ultragenyx Pharmaceutical Inc의 주식을 보유한 기관은 총 695곳이며, 이들이 보유한 주식의 총 가치는 약 106.19M로 전체 발행 주식의 107.82%를 차지합니다. 이는 2025Q4 대비 -1315399.00 증가한 수치입니다.
Ultragenyx Pharmaceutical Inc의 최대 수익원은 무엇인가요?
2026Q1 기준, Ultragenyx Pharmaceutical Inc의 Crysvita royalty revenue 부문이 가장 높은 매출을 기록했으며, 금액은 304.00M로 전체 매출의 45.17%를 차지했습니다.